Yan Li1, Suzanne E Schindler1, James G Bollinger1, Vitaliy Ovod1, Kwasi G Mawuenyega1, Michael W Weiner1, Leslie M Shaw1, Colin L Masters1, Christopher J Fowler1, John Q Trojanowski1, Magdalena Korecka1, Ralph N Martins1, Shorena Janelidze1, Oskar Hansson1, Randall J Bateman2. 1. From the Department of Neurology (Y.L., S.E.S., J.G.B., V.O., K.G.M., R.J.B.), Division of Biostatistics (Y.L.), Knight Alzheimer's Disease Research Center (S.E.S., R.J.B.), and Hope Center for Neurological Disorders (R.J.B.), Washington University School of Medicine, St. Louis, MO; Departments of Psychiatry, Radiology and Biomedical Imaging, Medicine, and Neurology (M.W.W.), Center for Imaging and Neurodegenerative Diseases, Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, University of California San Francisco; Department of Pathology and Laboratory Medicine (S.M.L., J.Q.T., M.K.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; The Florey Institute of Neuroscience and Mental Health (C.L.M., C.J.F.), University of Melbourne, Victoria; Edith Cowan University (R.N.M.), Joondalup, Australia; Department of Clinical Sciences, Clinical Memory Research Unit (S.J., O.H.), Lund University; and Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden. 2. From the Department of Neurology (Y.L., S.E.S., J.G.B., V.O., K.G.M., R.J.B.), Division of Biostatistics (Y.L.), Knight Alzheimer's Disease Research Center (S.E.S., R.J.B.), and Hope Center for Neurological Disorders (R.J.B.), Washington University School of Medicine, St. Louis, MO; Departments of Psychiatry, Radiology and Biomedical Imaging, Medicine, and Neurology (M.W.W.), Center for Imaging and Neurodegenerative Diseases, Northern California Institute for Research and Education, Department of Veterans Affairs Medical Center, University of California San Francisco; Department of Pathology and Laboratory Medicine (S.M.L., J.Q.T., M.K.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; The Florey Institute of Neuroscience and Mental Health (C.L.M., C.J.F.), University of Melbourne, Victoria; Edith Cowan University (R.N.M.), Joondalup, Australia; Department of Clinical Sciences, Clinical Memory Research Unit (S.J., O.H.), Lund University; and Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden. batemanr@wustl.edu.
Abstract
BACKGROUND AND OBJECTIVES: To determine the diagnostic accuracy of a plasma Aβ42/Aβ40 assay in classifying amyloid PET status across global research studies using samples collected by multiple centers that utilize different blood collection and processing protocols. METHODS: Plasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). Plasma Aβ42/Aβ40 was measured by a high precision immunoprecipitation mass spectrometry (IPMS) assay and compared to the reference standards of amyloid PET and CSF Aβ42/Aβ40. RESULTS: In the combined cohort of 465 participants, plasma Aβ42/Aβ40 had good concordance with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.80-0.87); concordance improved with the inclusion of APOE ε4 carrier status (AUC 0.88, 95% CI 0.85-0.91). The AUC of plasma Aβ42/Aβ40 with CSF amyloid status was 0.85 (95% CI 0.78-0.91) and improved to 0.93 (95% CI 0.89-0.97) with APOE ε4 status. These findings were consistent across the 3 cohorts, despite differences in protocols. The assay performed similarly in both cognitively unimpaired and impaired individuals. DISCUSSION: Plasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.
BACKGROUND AND OBJECTIVES: To determine the diagnostic accuracy of a plasma Aβ42/Aβ40 assay in classifying amyloid PET status across global research studies using samples collected by multiple centers that utilize different blood collection and processing protocols. METHODS: Plasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). Plasma Aβ42/Aβ40 was measured by a high precision immunoprecipitation mass spectrometry (IPMS) assay and compared to the reference standards of amyloid PET and CSF Aβ42/Aβ40. RESULTS: In the combined cohort of 465 participants, plasma Aβ42/Aβ40 had good concordance with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.80-0.87); concordance improved with the inclusion of APOE ε4 carrier status (AUC 0.88, 95% CI 0.85-0.91). The AUC of plasma Aβ42/Aβ40 with CSF amyloid status was 0.85 (95% CI 0.78-0.91) and improved to 0.93 (95% CI 0.89-0.97) with APOE ε4 status. These findings were consistent across the 3 cohorts, despite differences in protocols. The assay performed similarly in both cognitively unimpaired and impaired individuals. DISCUSSION: Plasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.
Authors: Pierrick Bourgeat; Vincent Doré; Jurgen Fripp; David Ames; Colin L Masters; Olivier Salvado; Victor L Villemagne; Christopher C Rowe Journal: Neuroimage Date: 2018-08-18 Impact factor: 6.556
Authors: John C Morris; Suzanne E Schindler; Lena M McCue; Krista L Moulder; Tammie L S Benzinger; Carlos Cruchaga; Anne M Fagan; Elizabeth Grant; Brian A Gordon; David M Holtzman; Chengjie Xiong Journal: JAMA Neurol Date: 2019-03-01 Impact factor: 18.302
Authors: Qiao-Xin Li; Victor L Villemagne; James D Doecke; Alan Rembach; Shannon Sarros; Shiji Varghese; Amelia McGlade; Katrina M Laughton; Kelly K Pertile; Christopher J Fowler; Rebecca L Rumble; Brett O Trounson; Kevin Taddei; Stephanie R Rainey-Smith; Simon M Laws; Joanne S Robertson; Lisbeth A Evered; Brendan Silbert; Kathryn A Ellis; Christopher C Rowe; S Lance Macaulay; David Darby; Ralph N Martins; David Ames; Colin L Masters; Steven Collins Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Flora H Duits; Pablo Martinez-Lage; Claire Paquet; Sebastiaan Engelborghs; Alberto Lleó; Lucrezia Hausner; José L Molinuevo; Erik Stomrud; Lucia Farotti; Inez H G B Ramakers; Magda Tsolaki; Constance Skarsgård; Ragnar Åstrand; Anders Wallin; Martin Vyhnalek; Marie Holmber-Clausen; Orestes V Forlenza; Laura Ghezzi; Martin Ingelsson; Erik I Hoff; Gerwin Roks; Alexandre de Mendonça; Janne M Papma; Andrea Izagirre; Mariko Taga; Hanne Struyfs; Daniel A Alcolea; Lutz Frölich; Mircea Balasa; Lennart Minthon; Jos W R Twisk; Staffan Persson; Henrik Zetterberg; Wiesje M van der Flier; Charlotte E Teunissen; Philip Scheltens; Kaj Blennow Journal: Alzheimers Dement Date: 2015-09-11 Impact factor: 21.566
Authors: Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Leslie M Shaw; Jalayne Arias; Kaj Blennow; Douglas Galasko; Jose Luis Molinuevo; Stephen Salloway; Suzanne Schindler; Maria C Carrillo; James A Hendrix; April Ross; Judit Illes; Courtney Ramus; Sheila Fifer Journal: Alzheimers Dement Date: 2018-10-10 Impact factor: 16.655
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Tim West; Kristopher M Kirmess; Matthew R Meyer; Mary S Holubasch; Stephanie S Knapik; Yan Hu; John H Contois; Erin N Jackson; Scott E Harpstrite; Randall J Bateman; David M Holtzman; Philip B Verghese; Ilana Fogelman; Joel B Braunstein; Kevin E Yarasheski Journal: Mol Neurodegener Date: 2021-05-01 Impact factor: 14.195
Authors: Adam M Brickman; Jennifer J Manly; Lawrence S Honig; Danurys Sanchez; Dolly Reyes-Dumeyer; Rafael A Lantigua; Patrick J Lao; Yaakov Stern; Jean Paul Vonsattel; Andrew F Teich; David C Airey; Nicholas Kyle Proctor; Jeffrey L Dage; Richard Mayeux Journal: Alzheimers Dement Date: 2021-02-13 Impact factor: 21.566
Authors: Nunzio Pomara; Davide Bruno; Chelsea Reichert Plaska; Jaime Ramos-Cejudo; Ricardo S Osorio; Anilkumar Pillai; Bruno P Imbimbo; Henrik Zetterberg; Kaj Blennow Journal: Transl Psychiatry Date: 2022-07-28 Impact factor: 7.989
Authors: Alberto Benussi; Valentina Cantoni; Jasmine Rivolta; Silvana Archetti; Anna Micheli; Nicholas Ashton; Henrik Zetterberg; Kaj Blennow; Barbara Borroni Journal: Alzheimers Res Ther Date: 2022-10-13 Impact factor: 8.823